Retinoblastoma, while the most common ocular cancer in children, is a rare. Only about 350 children are diagnosed with retinoblastoma in the United States each year. The tumor often presents when parents notice a wandering eye, an unusual white coloration of the pupil, or when the child’s physician notices the absence of the “red reflex” at the time of a physical exam.
The rarity of the tumor and the very high survival rates underlie the importance of an optimal management strategy that considers both the short- and long-term outcomes of any therapeutic decision. This can only be accomplished through a true team approach that is comprehensive and flexible enough to consider both local and national therapeutic strategies that are best for the child. Treatment of retinoblastoma has rapidly evolved to include chemoreduction of tumors that allow eye-salvage strategies that were previously unavailable.
Care of children with retinoblastoma at the University of Minnesota Amplatz Children’s Hospital is state of the art, team based, and individually focused. Pediatric ophthalmologists with experience in the diagnosis, staging, and local therapies along with pediatric oncologists with expertise in the disease and familiar with ever-evolving chemotherapy strategies are the cornerstones of this team.
Pathology, radiation oncology, and even interventional radiologists may all join the care team as the individualized therapeutic plan evolves. Through local, regional, and national collaborations our team of pediatric ophthalmologists, oncologists, and other specialists can provide life-long, individualized care for each child and family.
For further information or patient evaluations contact:
Dr. Jill Anderson, Pediatric Ophthalmology – 612-625-4400
Dr. Joseph Neglia, Pediatric Oncology – 612-626-2778
Drs. Anderson and Neglia can also be reached direclty through the University of Minnesota Amplatz Children’s Hospital Operator at 1-888-KIDS-UMN (1-888-543-7866).